Who can use Exkivity(Mobocertinib)?

Mobocertinib succinate capsules (mobocertinib) is a novel oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor developed by Takeda Pharmaceuticals.

Who can use Exkivity(Mobocertinib)?

Mobocertinib succinate capsules were first approved for marketing in the United States in 2021, followed by successive approvals in the European Union, Japan and other countries and regions. On January 11, 2023, the National Medical Products Administration (NMPA) conditionally approved the marketing of mobocertinib succinate capsules, a Class 1 innovative drug declared by Takeda Pharmaceuticals, through the priority review and approval process, but it has not yet been included in the medical insurance reimbursement.